Cargando…
Utility of Tissue Inhibitor Metalloproteinase-1 and Osteopontin as Prospective Biomarkers of Early Cardiovascular Complications in Type 2 Diabetes
AIM: This work investigated associations between tissue inhibitor metalloproteinase-1 and diabetic cardiovascular diseases in type 2 diabetic patients; also it investigated the role of osteopontin in the diagnosis of type 2 cardiovascular diabetes complications. SUBJECTS AND METHODS: These were exam...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Republic of Macedonia
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839439/ https://www.ncbi.nlm.nih.gov/pubmed/29531595 http://dx.doi.org/10.3889/oamjms.2018.081 |
_version_ | 1783304413134192640 |
---|---|
author | El-Din, Doaa Samir Salah Amin, Ahmed Ibrahim Egiza, Ahmed Osman |
author_facet | El-Din, Doaa Samir Salah Amin, Ahmed Ibrahim Egiza, Ahmed Osman |
author_sort | El-Din, Doaa Samir Salah |
collection | PubMed |
description | AIM: This work investigated associations between tissue inhibitor metalloproteinase-1 and diabetic cardiovascular diseases in type 2 diabetic patients; also it investigated the role of osteopontin in the diagnosis of type 2 cardiovascular diabetes complications. SUBJECTS AND METHODS: These were examined on eighty subjects, divided into three groups as follows: twenty volunteer healthy control subjects, thirty type 2 diabetes mellitus (DM) patients, and thirty cardiovascular, diabetic patients. Full clinical measurements were carried out, and the expression level of tissue inhibitor metalloproteinase-1 in blood samples was analysed by real-time PCR, using gene-specific primer pairs. Also osteopontin concentrations had been measured by the enzyme-linked immunosorbent assay. Data were tested statistically by parametric tests. RESULTS: The concentrations of osteopontin and the expression levels of tissue inhibitor metalloproteinase-1 were significantly increased in diabetic and cardiovascular diabetic groups compared to control group also they were significantly increased in the cardiovascular diabetic group compared to the diabetic group. CONCLUSION: Tissue inhibitor metalloproteinase-1 and osteopontin concentrations were significantly increased in diabetic patients with cardiovascular complications than other groups. |
format | Online Article Text |
id | pubmed-5839439 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Republic of Macedonia |
record_format | MEDLINE/PubMed |
spelling | pubmed-58394392018-03-12 Utility of Tissue Inhibitor Metalloproteinase-1 and Osteopontin as Prospective Biomarkers of Early Cardiovascular Complications in Type 2 Diabetes El-Din, Doaa Samir Salah Amin, Ahmed Ibrahim Egiza, Ahmed Osman Open Access Maced J Med Sci Clinical Science AIM: This work investigated associations between tissue inhibitor metalloproteinase-1 and diabetic cardiovascular diseases in type 2 diabetic patients; also it investigated the role of osteopontin in the diagnosis of type 2 cardiovascular diabetes complications. SUBJECTS AND METHODS: These were examined on eighty subjects, divided into three groups as follows: twenty volunteer healthy control subjects, thirty type 2 diabetes mellitus (DM) patients, and thirty cardiovascular, diabetic patients. Full clinical measurements were carried out, and the expression level of tissue inhibitor metalloproteinase-1 in blood samples was analysed by real-time PCR, using gene-specific primer pairs. Also osteopontin concentrations had been measured by the enzyme-linked immunosorbent assay. Data were tested statistically by parametric tests. RESULTS: The concentrations of osteopontin and the expression levels of tissue inhibitor metalloproteinase-1 were significantly increased in diabetic and cardiovascular diabetic groups compared to control group also they were significantly increased in the cardiovascular diabetic group compared to the diabetic group. CONCLUSION: Tissue inhibitor metalloproteinase-1 and osteopontin concentrations were significantly increased in diabetic patients with cardiovascular complications than other groups. Republic of Macedonia 2018-02-10 /pmc/articles/PMC5839439/ /pubmed/29531595 http://dx.doi.org/10.3889/oamjms.2018.081 Text en Copyright: © 2018 Doaa Samir Salah El-Din, Ahmed Ibrahim Amin, Ahmed Osman Egiza. http://creativecommons.org/licenses/CC BY-NC/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). |
spellingShingle | Clinical Science El-Din, Doaa Samir Salah Amin, Ahmed Ibrahim Egiza, Ahmed Osman Utility of Tissue Inhibitor Metalloproteinase-1 and Osteopontin as Prospective Biomarkers of Early Cardiovascular Complications in Type 2 Diabetes |
title | Utility of Tissue Inhibitor Metalloproteinase-1 and Osteopontin as Prospective Biomarkers of Early Cardiovascular Complications in Type 2 Diabetes |
title_full | Utility of Tissue Inhibitor Metalloproteinase-1 and Osteopontin as Prospective Biomarkers of Early Cardiovascular Complications in Type 2 Diabetes |
title_fullStr | Utility of Tissue Inhibitor Metalloproteinase-1 and Osteopontin as Prospective Biomarkers of Early Cardiovascular Complications in Type 2 Diabetes |
title_full_unstemmed | Utility of Tissue Inhibitor Metalloproteinase-1 and Osteopontin as Prospective Biomarkers of Early Cardiovascular Complications in Type 2 Diabetes |
title_short | Utility of Tissue Inhibitor Metalloproteinase-1 and Osteopontin as Prospective Biomarkers of Early Cardiovascular Complications in Type 2 Diabetes |
title_sort | utility of tissue inhibitor metalloproteinase-1 and osteopontin as prospective biomarkers of early cardiovascular complications in type 2 diabetes |
topic | Clinical Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839439/ https://www.ncbi.nlm.nih.gov/pubmed/29531595 http://dx.doi.org/10.3889/oamjms.2018.081 |
work_keys_str_mv | AT eldindoaasamirsalah utilityoftissueinhibitormetalloproteinase1andosteopontinasprospectivebiomarkersofearlycardiovascularcomplicationsintype2diabetes AT aminahmedibrahim utilityoftissueinhibitormetalloproteinase1andosteopontinasprospectivebiomarkersofearlycardiovascularcomplicationsintype2diabetes AT egizaahmedosman utilityoftissueinhibitormetalloproteinase1andosteopontinasprospectivebiomarkersofearlycardiovascularcomplicationsintype2diabetes |